AJP - Regu AJP: Gastrointestinal and Liver Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Regul Integr Comp Physiol 289: R299-R304, 2005. First published March 17, 2005; doi:10.1152/ajpregu.00269.2004
0363-6119/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/2/R299    most recent
00269.2004v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, C.-H.
Right arrow Articles by Verma, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, C.-H.
Right arrow Articles by Verma, S.

TRANSLATIONAL PHYSIOLOGY

Tetrahydrobiopterin deficiency exaggerates intimal hyperplasia after vascular injury

Chao-Hung Wang,1,3 Shu-Hong Li,1 Richard D. Weisel,1 Paul W. M. Fedak,1 Agnes Hung,3 Ren-Ke Li,1 Vivek Rao,1 Keith Hyland,2 Wen-Jin Cherng,3 Lee Errett,4 Yves Leclerc,4 Daniel Bonneau,4 David A. Latter,4 and Subodh Verma1,4

1Division of Cardiac Surgery, Toronto General Hospital, Toronto, Canada; 2Institute of Metabolic Disease, Baylor University Medical Center, Dallas, Texas; 3Cardiology Section, Department of Medicine, Chang Gung Medical College, Chang Gung Memorial Hospital, Keelung, Taiwan; and 4Division of Cardiac Surgery, St. Michael’s Hospital, Toronto, Canada

Submitted 27 April 2004 ; accepted in final form 8 February 2005

ABSTRACT

Decreased levels of tetrahydrobiopterin (BH4), an absolute cofactor for nitric oxide synthase (NOS), lead to uncoupling of NOS into a superoxide v. nitric oxide producing enzyme, and it is this uncoupling that links it to the development of vascular disease. However, the effects of in vivo deficiency of BH4 on neointimal formation after vascular injury have not been previously investigated. Hph-1 mice, which display 90% deficiency in guanine triphosphate cyclohydrolase I, the rate limiting enzyme in BH4 synthesis, were used. Hph-1 and wild-type mice, treated with either vehicle or BH4 (n = 15 per group), were subjected to wire-induced femoral artery injury, and NOS expression and activity, inflammation, cell proliferation, superoxide production, and neointimal formation were assessed. The major form of NOS expressed over vessel wall after vascular injury was endothelial NOS. Hph-1 mice exhibited lower NOS activity (2.8 ± 0.3 vs. 4.5 ± 0.4 pmol/min/mg protein, P < 0.01), and higher aortic superoxide content (5.2 ± 2.0 x 105 cpm vs. 1.6 ± 0.7 x 105 cpm, P < 0.01) compared with wild-type controls, indicating uncoupling of NOS. Treatment of hph-1 mice with BH4 significantly increased NOS activity (from 2.8 ± 0.3 to 4.1 ± 0.4 pmol·min–1·mg protein–1, P < 0.05), and attenuated superoxide production (from 5.2 ± 2.0 x 105 cpm to 0.8 ± 0.7 x 105 cpm, P < 0.05). Hph-1 mice also had higher inflammatory reactions and more cell proliferation after vascular injury. Furthermore, hph-1 mice responded by a marked increase in neointimal formation at 4 wk after vascular injury, compared with wild-type controls (intima:media ratio: 4.5 ± 0.5 vs. wild-type 0.7 ± 0.1, P < 0.001). Treatment of hph-1 mice with BH4 prevented vascular injury-induced increase in neointimal formation (intima:media ratio: 1.4 ± 0.1 vs. hph-1, P < 0.001). Treatment had no effect on wild-type controls. In summary, we describe, for the first time, that in vivo BH4 deficiency facilitates neointimal formation after vascular injury. Modulation of BH4 bioavailability is an important therapeutic target for restenosis.

restenosis; superoxide; nitric oxide synthase



Address for reprint requests and other correspondence: S. Verma, Division of Cardiac Surgery, St. Michael’s Hospital, 30 Bond St., Queen Wing, Suite 8–003H, Toronto, ON, Canada, M5B 1W8 (E-mail: Subodh.Verma{at}sympatico.ca)




This article has been cited by other articles:


Home page
HypertensionHome page
S. Verma and M. K. Gupta
Aliskiren Improves Nitric Oxide Bioavailability and Limits Atherosclerosis
Hypertension, September 1, 2008; 52(3): 467 - 469.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.